Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital (LAMSA)

Assistance Publique - Hôpitaux de Paris

Status

Not yet enrolling

Conditions

Acute Myeloid Leukemia

Study type

Observational

Funder types

Other

Identifiers

NCT05558943

APHP211337

Details and patient eligibility

About

AML in adults represents a group of heterogeneous diseases; the prognosis remains poor despite significant therapeutic advances in recent years. In order to optimize patient care, it is necessary to have "real life" data that exhaustively reports on the patients treated in our department. The objective of this study is:

To describe the AML treated within the hematology department
To optimize the management of patients with AML.

Full description

Current state of knowledge:

Acute myeloblastic leukemia are the most common leukemias in adults. This pathology is very heterogeneous. It has a poor prognosis despite numerous therapeutic advances. The lack of randomized clinical trials can make certain treatment decisions difficult. In addition, patients with comorbidities or the elderly are most often excluded from these trials even though they represent a significant proportion of new diagnoses.

Objectives:

Primary objective Evaluate the overall survival of adult patients treated for AML in our hematology department at Saint-Antoine Hospital.

Secondary objectives

Evaluate early mortality at 30 days and 60 days post-induction
Evaluate the CR/CRi rate after induction
Evaluate the toxicity of the treatments
Evaluate the relapse-free survival time
Assess the prognostic value of JC-1 at diagnosis
Evaluate the proportion of patients eligible for intensive treatment and/or allograft
Evaluate the side effects of the treatments undertaken
Describe the molecular and cytogenetic characteristics of hemopathies at diagnosis and at relapse

Duration of study:

Retrospective cohort (cohort A): patients diagnosed between junuary1,2010 and May 30,2022 Prospective cohort (cohort B): patients diagnosed between June 1, 2022 and December 31, 2023. A follow-up of 2 years will be necessary after the end of treatment.

The end of follow-up is estimated at December 2025 for the entire cohort.

Data collection:

Collection of clinical and biological data in the patient's medical file via the Orbis software

Population:

Adult patients treated for AML at Saint-Antoine hospital

Enrollment

750 estimated patients

Sex

All

Ages

18+ years old

Volunteers